Literature DB >> 11584191

Anticoagulation in the elderly.

M C Henderson1, R H White.   

Abstract

Oral anticoagulation therapy has demonstrated benefit in the treatment and prevention of a variety of thromboembolic disorders. Most individuals who receive oral anticoagulant therapy are elderly patients with nonvalvular atrial fibrillation and acute or recurrent venous thromboembolism. Anticoagulation in elderly patients poses unique challenges for the practicing clinician because they are simultaneously at higher risk for recurrent thromboembolism and major bleeding, including catastrophic intracranial hemorrhage. The pharmacology of warfarin in the elderly is reviewed, including important drug interactions and current dosing recommendations for elderly patients. Evidence of the benefits and risks of oral anticoagulation therapy are reviewed for patients with atrial fibrillation and venous thromboembolism. This information should enable practitioners to better assess the relative risks and benefit of oral anticoagulation therapy to guide treatment decisions in the elderly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584191     DOI: 10.1097/00063198-200109000-00020

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  2 in total

1.  Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.

Authors:  Avi Levin; Moshe Ben-Artzi; Pazit Beckerman; Guy Haber; David Varon; Arie Ben-Yehuda; Mordechai Muszkat
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

2.  A team-based approach to warfarin management in long term care: a feasibility study of the MEDeINR electronic decision support system.

Authors:  Alexandra Papaioannou; Courtney C Kennedy; Glenda Campbell; Jacqueline B Stroud; Luqi Wang; Lisa Dolovich; Mark A Crowther
Journal:  BMC Geriatr       Date:  2010-06-10       Impact factor: 3.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.